TELA Bio Inc
TELA1.130USD
-0.010-0.88%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
45.59MMarket Cap
LossP/E TTM
More Details of TELA Bio Inc Company
TELA Bio, Inc. is a commercial-stage medical technology company. The Company is focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy. Its first portfolio of products, the OviTex Reinforced Tissue Matrix (OviTex), addresses unmet needs in hernia repair and abdominal wall reconstruction. Its OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair. The Company's OviTex products include OviTex 1S, OviTex 2S, OviTex LPR, and OviTex IHR. Its second portfolio of products, the OviTex PRS Reinforced Tissue Matrix (OviTex PRS), addresses unmet needs in plastic and reconstructive surgery. OviTex PRS is indicated for use in implantation to reinforce soft tissue where weakness exists in patients requiring soft-tissue repair.
TELA Bio Inc Info
Ticker SymbolTELA
Company nameTELA Bio Inc
IPO dateNov 08, 2019
CEOKoblish (Antony)
Number of employees209
Security typeOrdinary Share
Fiscal year-endNov 08
Address1 Great Valley Parkway, Suite 24
CityMALVERN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code19355
Phone14843202930
Websitehttps://www.telabio.com/
Ticker SymbolTELA
IPO dateNov 08, 2019
CEOKoblish (Antony)
Company Executives of TELA Bio Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Antony Koblish
Mr. Antony Koblish
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
339.79K
-21.60%
Mr. Jeffrey (Jeff) Blizard
Mr. Jeffrey (Jeff) Blizard
President
President
112.75K
+1318.24%
Mr. Paul Talmo
Mr. Paul Talmo
Chief Technology Officer
Chief Technology Officer
61.37K
-27.72%
Mr. Kurt Azarbarzin
Mr. Kurt Azarbarzin
Independent Director
Independent Director
14.22K
+126.79%
Mr. Douglas G. (Doug) Evans
Mr. Douglas G. (Doug) Evans
Independent Chairman of the Board
Independent Chairman of the Board
14.22K
+126.79%
Ms. Federica F. O'Brien
Ms. Federica F. O'Brien
Independent Director
Independent Director
14.22K
+126.79%
Dr. Betty Jo Rocchio
Dr. Betty Jo Rocchio
Independent Director
Independent Director
11.93K
--
Mr. Vince J. Burgess
Mr. Vince J. Burgess
Independent Director
Independent Director
--
--
Mr. Greg Firestone
Mr. Greg Firestone
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. William Plovanic
Mr. William Plovanic
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Antony Koblish
Mr. Antony Koblish
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
339.79K
-21.60%
Mr. Jeffrey (Jeff) Blizard
Mr. Jeffrey (Jeff) Blizard
President
President
112.75K
+1318.24%
Mr. Paul Talmo
Mr. Paul Talmo
Chief Technology Officer
Chief Technology Officer
61.37K
-27.72%
Mr. Kurt Azarbarzin
Mr. Kurt Azarbarzin
Independent Director
Independent Director
14.22K
+126.79%
Mr. Douglas G. (Doug) Evans
Mr. Douglas G. (Doug) Evans
Independent Chairman of the Board
Independent Chairman of the Board
14.22K
+126.79%
Ms. Federica F. O'Brien
Ms. Federica F. O'Brien
Independent Director
Independent Director
14.22K
+126.79%
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
By BusinessUSD
Name
Revenue
Proportion
OviTex
24.60M
63.53%
OviTex PRS
13.38M
34.55%
Other
744.00K
1.92%
Relevant data have not been disclosed by the company yet.
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
OviTex
24.60M
63.53%
OviTex PRS
13.38M
34.55%
Other
744.00K
1.92%
Shareholding Stats
Updated: Sat, Nov 15
Updated: Sat, Nov 15
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
EW Healthcare Partners
17.62%
Nantahala Capital Management, LLC
11.68%
North Run Capital, LP
8.41%
Lytton (Laurence W)
6.55%
SilverArc Capital Management, LLC
6.36%
Other
49.38%
Shareholders
Shareholders
Proportion
EW Healthcare Partners
17.62%
Nantahala Capital Management, LLC
11.68%
North Run Capital, LP
8.41%
Lytton (Laurence W)
6.55%
SilverArc Capital Management, LLC
6.36%
Other
49.38%
Shareholder Types
Shareholders
Proportion
Hedge Fund
33.32%
Venture Capital
17.62%
Investment Advisor
9.79%
Investment Advisor/Hedge Fund
8.67%
Individual Investor
8.59%
Research Firm
1.77%
Other
20.24%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
171
28.74M
72.54%
-9.88M
2025Q2
185
33.40M
84.44%
-6.87M
2025Q1
191
33.22M
84.09%
-7.97M
2024Q4
187
31.75M
80.76%
+976.11K
2024Q3
178
22.55M
84.95%
-6.37M
2024Q2
170
20.61M
83.03%
-5.54M
2024Q1
157
22.19M
89.70%
-5.95M
2023Q4
151
21.96M
89.44%
-4.89M
2023Q3
146
22.32M
90.91%
-4.91M
2023Q2
142
22.34M
91.32%
+1.25M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
EW Healthcare Partners
4.11M
10.38%
--
--
Jun 30, 2025
Nantahala Capital Management, LLC
5.11M
12.9%
-1.00
-0.00%
Jun 30, 2025
North Run Capital, LP
3.68M
9.3%
+1.70M
+85.75%
Mar 31, 2025
Lytton (Laurence W)
2.72M
6.88%
+271.93K
+11.09%
Jun 30, 2025
SilverArc Capital Management, LLC
2.78M
7.02%
+8.51K
+0.31%
Jun 30, 2025
Stonepine Capital Management, LLC
2.08M
5.26%
+28.54K
+1.39%
Jun 30, 2025
The Vanguard Group, Inc.
1.91M
4.83%
-16.59K
-0.86%
Jun 30, 2025
Dafna Capital Management, LLC
1.44M
3.64%
--
--
Jun 30, 2025
Perkins Capital Management, Inc.
875.87K
2.21%
-34.75K
-3.82%
Jun 30, 2025
Citi Investment Research (US)
750.00K
1.89%
--
--
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0.01%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 Growth ETF
0%
iShares Russell 2000 ETF
0%
Global X Russell 2000 ETF
0%
Global X Russell 2000 Covered Call ETF
0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0%
ProShares UltraPro Russell2000
0%
Proshares Ultra Russell 2000
0%
iShares Micro-Cap ETF
Proportion0.01%
ProShares Hedge Replication ETF
Proportion0%
iShares Russell 2000 Growth ETF
Proportion0%
iShares Russell 2000 ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
Global X Russell 2000 Covered Call ETF
Proportion0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of TELA Bio Inc?
The top five shareholders of TELA Bio Inc are:
EW Healthcare Partners holds 4.11M shares, accounting for 10.38% of the total shares.
Nantahala Capital Management, LLC holds 5.11M shares, accounting for 12.90% of the total shares.
North Run Capital, LP holds 3.68M shares, accounting for 9.30% of the total shares.
Lytton (Laurence W) holds 2.72M shares, accounting for 6.88% of the total shares.
SilverArc Capital Management, LLC holds 2.78M shares, accounting for 7.02% of the total shares.
EW Healthcare Partners holds 4.11M shares, accounting for 10.38% of the total shares.
Nantahala Capital Management, LLC holds 5.11M shares, accounting for 12.90% of the total shares.
North Run Capital, LP holds 3.68M shares, accounting for 9.30% of the total shares.
Lytton (Laurence W) holds 2.72M shares, accounting for 6.88% of the total shares.
SilverArc Capital Management, LLC holds 2.78M shares, accounting for 7.02% of the total shares.
What are the top three shareholder types of TELA Bio Inc?
The top three shareholder types of TELA Bio Inc are:
EW Healthcare Partners
Nantahala Capital Management, LLC
North Run Capital, LP
EW Healthcare Partners
Nantahala Capital Management, LLC
North Run Capital, LP
How many institutions hold shares of TELA Bio Inc (TELA)?
As of 2025Q3, 171 institutions hold shares of TELA Bio Inc, with a combined market value of approximately 28.74M, accounting for 72.54% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -11.90%.
What is the biggest source of revenue for TELA Bio Inc?
In FY2025Q2, the OviTex business generated the highest revenue for TELA Bio Inc, amounting to 24.60M and accounting for 63.53% of total revenue.
